"Health" withdraw certain drugs containing the "Valsartan"

The Ministry of Health and Community Protection issued a circular with the preventive withdrawal of certain pharmaceutical products containing the active ingredient Valsartan, used for the treatment of blood pressure and manufactured by the Zhejiang Huahai Pharmaceutical Company because of contamination of the active substance. The ministerial decision to withdraw certain products containing Valassartan was published on the basis of the report of the EMA, which confirms the contamination of the active substance "Valsartan" manufactured by the company "Zhejiang Huahai Pharmaceutical" in China with "NDMA" carcinogen. The effectiveness is used in the treatment of cardiovascular disease due to The Ministry reported that the circular addressed to directors of medical regions and directors of public and private hospitals, doctors, pharmacists and assistant pharmacists, directors of government pharmacies and issued after the revision of the Ministerial Resolution No. 2010 on the announcement of the withdrawal or suspension or the Pharmaceuticals and the public interest The circular included a list of the drugs concerned, noting that the products Receipts were registered with the Drug Administration of the Ministry of Health and Community Protection.

The Ministry Required All Health Professionals Do Not Describe (19659002) The Ministry has confirmed that all drugs containing "Valsartan", manufactured with the same active substance from other sources are intact and unaffected . Referring to the receipt of an official message from the company "Novartis", which developed the drug indicating that its products containing the substance "Valsartan", especially drugs, "Diovan Co-Diovan Entresto, Exforge" only are not affected. The active substance comes from an external resource where suction is used

The Ministry of Health and Community Protection has regularly tested random samples of drugs at the Laboratory of Quality Control and Research of the Medical Park and Dubai Medical Research Center, as well as its ongoing contacts with the FDA.

Community members appealed to the Ministry of Health and the relevant health authorities to review official information on any medical issue or medical warning for medicines and medical devices, noting that if the public wishes to verify any information Regarding the safety of health products registered in the state and circulars issued by the Ministry can communicate with by e-mail "[email protected] link Ooabbar courier service" Tmna. «